IOVS Journal Watch
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lai, C.-C.
Right arrow Articles by Tsao, Y.-P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lai, C.-C.
Right arrow Articles by Tsao, Y.-P.
(Investigative Ophthalmology and Visual Science. 2001;42:2401-2407.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Suppression of Choroidal Neovascularization by Adeno-associated Virus Vector Expressing Angiostatin

Chi-Chun Lai1, Wei-Chi Wu1, Show-Li Chen2, Xiao Xiao3, Tzung-Chieh Tsai4, Shyh-Jer Huan2, Tun-Lu Chen1, Ray Jui-Fang Tsai1 and Yeou-Ping Tsao1

1 From the Department of Ophthalmology, Chang-Gung Memorial Hospital, Taoyuan, Taiwan; the 2 Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan; the 3 Department of Molecular Genetics and Biochemistry, University of Pittsburgh, Pennsylvania; and the 4 Department of Medical Research, Veteran’s General Hospital, Taipei, Taiwan.

PURPOSE. To test the efficacy of a recombinant adeno-associated virus (rAAV) vector that expresses mouse angiostatin in suppressing experimental choroidal neovascularization (CNV) in a rat model.

METHODS. An rAAV vector, rAAV-angiostatin, was constructed to deliver the mouse angiostatin gene. rAAV-angiostatin and a control virus, rAAV-lacZ, were delivered in vivo by subretinal injection in Brown Norway rats, and the delivery was confirmed by reverse-transcriptase polymerase chain reaction (RT-PCR). For a CNV suppression experiment, CNV was generated by fundus krypton laser photocoagulation 7 days after the viral vector injection and was evaluated by fluorescein angiography (FA) and histology. Apoptosis in retina was analyzed using the TUNEL assay. Inflammation in the retina was investigated by immunohistochemistry, using antibodies that recognize lymphocytes.

RESULTS. rAAV-angiostatin injection led to sustained expression of the angiostatin gene in chorioretinal tissue for up to150 days. FA analysis revealed significant reduction of the average sizes of CNV lesions in rAAV-angiostatin–injected eyes when compared with rAAV-lacZ–injected eyes at both 14 (P = 0.019) and 150 (P = 0.010) days after injection. Moreover, histologic analysis of CNV lesions also revealed significantly smaller lesions in rAAV-angiostatin–injected eyes (P = 0.004). As for adverse effects, rAAV-angiostatin injection did not cause inflammation or apoptosis of cells in retina and choroid.

CONCLUSIONS. This is the first report that subretinal injection of rAAV-angiostatin can significantly reduce the sizes of CNV lesions. This and the absence of apoptosis and inflammation in chorioretinal tissue indicate the feasibility of a gene therapy approach for treatment of CNV disease.




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
T.-C. Tsai, Y.-L. Lee, W.-C. Hsiao, Y.-P. Tsao, and S.-L. Chen
NRIP, a Novel Nuclear Receptor Interaction Protein, Enhances the Transcriptional Activity of Nuclear Receptors
J. Biol. Chem., May 20, 2005; 280(20): 20000 - 20009.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
H. Akiyama, T. Tanaka, H. Itakura, H. Kanai, T. Maeno, H. Doi, M. Yamazaki, K. Takahashi, Y. Kimura, S. Kishi, et al.
Inhibition of Ocular Angiogenesis by an Adenovirus Carrying the Human von Hippel-Lindau Tumor-Suppressor Gene In Vivo
Invest. Ophthalmol. Vis. Sci., May 1, 2004; 45(5): 1289 - 1296.
[Abstract] [Full Text] [PDF]


Home page
Arch OphthalmolHome page
W.-Y. Shen, S. Y. Lee, I. Yeo, C.-M. Lai, R. Mathur, D. Tan, I. J. Constable, and P. E. Rakoczy
Predilection of the Macular Region to High Incidence of Choroidal Neovascularization After Intense Laser Photocoagulation in the Monkey
Arch Ophthalmol, March 1, 2004; 122(3): 353 - 360.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
Y. Yanagi, Y. Tamaki, Y. Inoue, R. Obata, K. Muranaka, and N. Homma
Subconjunctival Doxifluridine Administration Suppresses Rat Choroidal Neovascularization through Activated Thymidine Phosphorylase
Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 751 - 754.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
W.-C. Wu, C.-C. Lai, S.-L. Chen, X. Xiao, T.-L. Chen, R. J.-F. Tsai, S.-W. Kuo, and Y.-P. Tsao
Gene Therapy for Detached Retina by Adeno-Associated Virus Vector Expressing Glial Cell Line-Derived Neurotrophic Factor
Invest. Ophthalmol. Vis. Sci., November 1, 2002; 43(11): 3480 - 3488.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
Y. Yanagi, Y. Tamaki, R. Obata, K. Muranaka, N. Homma, H. Matsuoka, and H. Mano
Subconjunctival Administration of Bucillamine Suppresses Choroidal Neovascularization in Rat
Invest. Ophthalmol. Vis. Sci., November 1, 2002; 43(11): 3495 - 3499.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Association for Research in Vision and Ophthalmology